Immuno-Oncology Drugs GLS-012 Alone & in Combination GLS-010 Treating With Advanced Patients Solid Tumors

Solid Tumor Clinical Trial

Official title:

A Phase I/II Study Evaluating the Safety, Tolerability and Preliminary Efficacy of GLS-012 Monotherapy and in Combination With GLS-010 in Patients With Advanced Solid Tumors After Progression on Standard Treatment (Triumph-01)

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05909436
• Other study ID #: GLS-012-11
• Status: Recruiting
• Phase: Phase 1/Phase 2
• Start date: October 31, 2022
• Est. completion date: December 2026

Study information

• Verified date: May 2023
• Source: Guangzhou Gloria Biosciences Co., Ltd.
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a phase I/II study to investigate the safety, tolerability, and preliminary efficacy of GLS-012 monotherapy and in combination with GLS-010 in subjects with advanced solid rumor after progression on standard treatment.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 107
• Est. completion date: December 2026
• Est. primary completion date: December 2026
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 75 Years

Eligibility

Inclusion Criteria:

1. Patients who are willing to sign the informed consent form;

2. Aged 18-75 years, male or female;

3. Histologically confirmed diagnosis of a solid tumor;

4. Patients with advanced solid tumors after progression on standard treatment;

5. Subjects must have at least 1 measurable target lesion according to RECIST version 1.1;

6. Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1;

7. Life expectancy more than 12 weeks;

8. Adequate organ function and bone marrow function as indicated by the screening assessments in the screening period;

9. Women of childbearing potential must use highly effective contraception during the study period and at least 6 months after the last study drug administration, and must have a negative blood pregnancy test within 3 days before study enrollment.

Exclusion Criteria:

1. Patients with irAEs of grade = 3 in the previous immunotherapy, and the AEs of the last anti-tumor treatment have not recovered to grade = 1, except for hypothyroidism/hyperthyroidism and dermatitis that have recovered to grade = 2, and AEs with no safety risks judged by the investigators, for example, alopecia.

2. Patients with primary or secondary immunodeficiency, or patients who are receiving long-term systemic steroid therapy or any other form of immunosuppressive therapy within 7 days before randomization.

3. Use of corticosteroids or other immunosuppressants for systemic treatment within 14 days before the first study drug administration;

4. Known central nervous system (CNS) metastases;

5. Patients with severe hypersensitivity to macromolecular protein preparations/monoclonal antibodies in the past.

6. Patients with other malignant tumors within 5 years before screening, except cured cervical carcinoma in situ and cured skin basal cell carcinoma.

7. Cardiac clinical symptoms or diseases that are not well controlled.

8. Known hereditary or acquired bleeding and thrombosis tendency.

9. Patients with congenital or acquired immunodeficiency disorders (such as HIV-infection), or a history of organ transplantation.

10. Patients complying with any of hepatitis B surface antigen (HBsAg) positive and HBV-DNA copies being more than 2500 copies/ml (or 500 IU/ml); or positive HCV-RNA;

11. Patients with poor compliance or other conditions that are not suitable to participate in the clinical trial, as considered by the investigator.

Related Conditions & MeSH terms

• Neoplasms
• Solid Tumor

Intervention

Drug:
• GLS-012
In the dose escalation stage of GLS-012 monotherapy, RP2D will be determined. All subjects will receive GLS-012 intravenously Q3W. In the expansion stage of GLS-012 monotherapy, subjects will receive up to 17 doses of GLS-012 at the RP2D administered Q3W. In the dose escalation stage of GLS-012 combination with GLS-010, RP2D of GLS-012 in combination with a fixed-dose GLS-010 will be determined. All subjects will receive GLS-012 and GLS-010 intravenously Q3W. In the expansion stage of GLS-012 combination with GLS-010, subjects will receive up to 35 doses of GLS-012 at the RP2D and GLS-010 at a fixed dose administered Q3W.
• GLS-010
In the dose escalation stage of GLS-012 combination with GLS-010, RP2D of GLS-012 in combination with a fixed-dose GLS-010 will be determined. All subjects will receive GLS-012 and GLS-010 intravenously Q3W. In the expansion stage of GLS-012 combination with GLS-010, subjects will receive up to 35 doses of GLS-012 at the RP2D and GLS-010 at a fixed dose administered Q3W.

Locations

Country	Name	City	State
China	Beijing Cancer Hospital	Beijing

Sponsors (1)

Lead Sponsor	Collaborator
Guangzhou Gloria Biosciences Co., Ltd.

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	Receptor occupancy (RO) of GLS-012 in the dose escalation stage of GLS-012 monotherapy		Up to approximately 4.5 months
Primary	Number of Participants with a Dose-Limiting Toxicity (DLT) and MTD in the dose escalation stage		Up to 21 days after the first dose
Primary	Number of participants with treatment-related adverse events of GLS-012 monotherapy and in combination with GLS-010 in the expansion stage as assessed by CTCAE V5.0		Up to approximately 24 months
Secondary	Maximum plasma concentration (Cmax) of GLS-012 monotherapy and in combination with GLS-010		Up to approximately 4.5 months
Secondary	Elimination half-life (T1/2) of GLS-012 monotherapy and in combination with GLS-010		Up to approximately 4.5 months
Secondary	Objective response rate (ORR)		Up to approximately 24 months
Secondary	Disease control rate (DCR)		Up to approximately 24 months
Secondary	Preliminary anti-tumor activity: Duration of response (DOR), time to response (TTR), progression free survival (PFS), overall survival (OS)		Up to approximately 24 months
Secondary	Duration of response (DOR)		Up to approximately 24 months
Secondary	Time to response (TTR)		Up to approximately 24 months
Secondary	Progression free survival (PFS)		Up to approximately 24 months
Secondary	Overall survival (OS)		Up to approximately 24 months